ASCIA Transplantation and Primary Immunodeficiency (TAPID) 2025 Update

Introduction Inborn errors of immunity (IEIs) include primary immunodeficiencies (PID) and are a group of more than 550 potentially serious chronic medical conditions. TAPID (transplantation and primary immunodeficiency [PID]) is an important and ongoing expert collaboration between clinical immunologists, transplant physicians, and international experts, facilitated by the Australasian Society of Clinical Immunology and Allergy (ASCIA). The main objectives of TAPID are to enable complex PID and transplantation cases to be peer reviewed and discussed in a confidential expert forum and to publish guidelines. Method TAPID meetings involve representatives from major centres in Australia and New Zealand that have patients with PID and other inborn errors of immunity (IEIs), who are candidates for haematopoietic stem cell transplant (HSCT). There are currently more than 230 TAPID members, including 140 ASCIA members. The TAPID collaboration was initiated in May 2013, and since then there have been monthly virtual meetings. In-person meetings have been held in February 2014, May 2017, May 2018, May 2019, April 2023, May 2024, and May 2025. A TAPID case discussion form needs to be completed for every deidentified case to be discussed at TAPID meetings and circulated by email to the group prior to the meeting. A template form is available on the ASCIA website www.allergy.org.au/about-ascia/ascia-initiatives/tapid. Results From 2014 to 2025, a total of 233 cases have been discussed at TAPID meetings, including 129 cases since September 2018, as shown in the graph below. The cases are deidentified; however, the regions are specified. Conclusion The ASCIA TAPID collaboration continues to enable confidential expert discussion of patients with PID and other IEI, who are candidates for HSCT. TAPID meetings contribute to a team-based approach to management and transplantation, leading to improved patient outcomes.